We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Caribou Biosciences Inc (CRBU) NPV

Sell:$7.78 Buy:$7.79 Change: $0.12 (1.52%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.12 (1.52%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.12 (1.52%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Caribou Biosciences, Inc. is a clinical-stage genome-editing biopharmaceutical company. The Company is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. It is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. The Company’s lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-020.

Contact details

2929 7TH STREET, STE 120
United States
+1 (510) 9826030

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$710.99 million
Shares in issue:
88.43 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Rachel Haurwitz
    President, Chief Executive Officer, Co-Founder, Director
  • Jason O'byrne
    Chief Financial Officer
  • Reigin Zawadzki
    Chief People Officer
  • Tim Kelly
    Chief Technology Officer
  • Steven Kanner
    Chief Scientific Officer
  • Ruhi Khan
    Chief Business Officer
  • Barbara McClung
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.